Hola,
Are you new here?

I have an account

¿Te ayudamos?

Ejemplos de búsqueda

Vídeos Explicativos

PROCROP

financed

Closed

Professional cross priming for ovary and prostate cancer

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop... see more

28/02/2021

FUNOACION PARA LA...

8M€

Project Budget: 8M€

Project leader

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 8 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2021-02-28

PHC-13-2014: New therapies for chronic non-commu... Scope:Specific challenge: Chronic non-communicable diseases represent a significant burden on indivi...

I+D

Cerrada does 11 years

0% 76% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

FUNOACION PARA LA INVESTIG

1.19M€ | Leader

LUIS CALVO SANZ

1.49M€ | participant

MILTENYI BIOTEC GMBH

1.35M€ | participant

CHUV

1.22M€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 70 months Date Start: 2015-04-07
End date: 2021-02-28

Project leader

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Project Budget 8M€

participation deadline Sin fecha límite de participación.

Project description Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy. The project applies recent compelling knowledge on the identity of the main antigen-presenting DC subsets for vaccine elicitation of cytotoxic T lymphocytes endowed with the ability to seek and destroy tumour cells (such immune mechanism is termed crosspriming). This unique opportunity for superior DCs for immunotherapy comes from the fact that Miltenyi, a successful European biotech company, has the necessary proprietary reagents (anti-BDCA-3 monoclonal antibody and immunomagnetic selection technology), as well as the expertise to clinically develop a strategy of DC isolation and short-term cell culture for immunotherapy. From the point of view of the tumor antigens, processed autologous tumor material will be mixed with defined common tumor antigens in the form of recombinant proteins. This novel combination will permit stronger and broader antitumor immune responses and more accurate monitoring of the ensuing immunity against the tumors. These features should make the novel DC vaccine more efficacious than the currently US-approved DC vaccine PROVENGE and other DCs preparations undergoing trials, such as those derived from monocytes. Three of the leading groups in immunotherapy of cancer in Europe would join forces to develop this individualized cell therapy technology in clinical trials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers